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SUMMARY
Rising numbers of campylobacteriosis case notiﬁcations in Switzerland resulted in an increased
attention to acute gastroenteritis (AG) in general. Patients with a laboratory-conﬁrmed
Campylobacter infection perceive their disease as severe and around 15% of these patients are
hospitalized. This study aimed at estimating healthcare costs due to AG and campylobacteriosis
in Switzerland. We used ofﬁcial health statistics, data from different studies and expert opinion
for estimating individual treatment costs for patients with different illness severity and for
extrapolating overall costs due to AG and campylobacteriosis. We estimated that total Swiss
healthcare costs resulting from these diseases amount to €29–45 million annually. Data
suggest that patients with AG consulting a physician without a stool diagnostic test account
for €9·0–24·2 million, patients with a negative stool test result for Campylobacter spp. for
€12·3 million, patients testing positive for Campylobacter spp. for €1·8 million and hospitalized
campylobacteriosis patients for €6·5 million/year. Healthcare costs of campylobacteriosis are high
and most likely increasing in Switzerland considering that campylobacteriosis case notiﬁcations
steadily increased in the past decade. Costs and potential cost savings for the healthcare system
should be considered when designing sectorial and cross-sectorial interventions to reduce the
burden of human campylobacteriosis in Switzerland.
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INTRODUCTION
Since 1995 Campylobacter spp. has been the most fre-
quently reported gastrointestinal bacterial pathogen in
humans in Switzerland [1] and since 2005 in the
European Union (EU) [2]. An estimated 9·25 million
cases of campylobacteriosis occurred in 2009 in the
27 EU member states, of which around 2% were
reported [3]. Havelaar et al. estimated the ‘true’ inci-
dence rate of campylobacteriosis in these countries
at 30–13 500/100 000 population (350/100 000 in
Switzerland).
In Switzerland, positive test results for Campylobacter
spp. have to be notiﬁed by diagnostic laboratories to the
Federal Ofﬁce of Public Health (FOPH) since 1988 [4].
In 2012, 8480 campylobacteriosis cases were registered
within the National Notiﬁcation System for Infectious
Diseases (NNSID), which is the highest number
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reported so far [1]. This corresponds to a notiﬁcation
rate of 105 cases/100 000 resident population in
Switzerland. The extent to which campylobacteriosis
contributes to the public health burden of acute gastro-
intestinal illness is unknown. In The Netherlands, about
twice the population size of Switzerland, approximately
4·8 million cases of gastroenteritis occur annually,
whereby 220 000 patients need medical consultation [5].
A study among 69 general practitioners (GPs) con-
cluded a rising awareness of campylobacteriosis as a
public health problem in Switzerland (Supplementary
material). Despite its mostly self-limiting nature, the
health burden of campylobacteriosis in the Swiss popu-
lation may be signiﬁcantly higher than ﬁgures from the
NNSID indicate. Severe cases and complications such
as Guillain–Barré syndrome, reactive arthritis and
post-infectious irritable bowel syndrome amplify the
burden of disease and in particular the economic
burden [6–8].
The estimated economic burden (equating health-
care costs at large, including, e.g. loss of productivity
and/or transportation and other direct and indirect
non-healthcare costs) of gastrointestinal infections or
foodborne illnesses in high-income countries varies
between €14 (Australia [9]) and €1305 (United States
[10]) per case in the community ([9–20] in Table 1).
Thereby, healthcare costs account for €3–155/case in
the community [9–20]. This wide range is partially
due to heterogeneity in case deﬁnitions and deﬁnitions
of economic burden. The yearly costs for gastroenter-
itis due to 14 food-related pathogens and associated
sequelae in The Netherlands were estimated at around
€468 million [11].
For campylobacteriosis, the estimated economic
burden per case varies, ranging from €117 (The
Netherlands [17]) to €6141 (United States [12]) ([8,
10–12, 17, 20, 26] in Table 2). Healthcare costs of
campylobacteriosis cases were estimated at €8/case
in New Zealand, €82–280 in The Netherlands and
€163–253 in the United States ([8, 10–12, 20] in
Table 2). These numbers are difﬁcult to compare as
case deﬁnitions and cost items included vary between
studies. For example, sequelae due to campylobacter-
iosis were considered in some studies while in others
they were not. Campylobacteriosis-associated acute
gastroenteritis (AG) accounts for approximately
108 000 cases/year in The Netherlands, causing an-
nual societal costs of about €81·5 million (including
sequelae) [11]. In the EU, campylobacteriosis cases ac-
count for expenditures of public health systems and
for productivity losses of around €2·4 billion/year
according to the European Food Safety Authority
[28]. The economic burden highlights the importance
of this widespread and common disease.
A quantiﬁcation of healthcare costs due to AG and/
or campylobacteriosis in Switzerland is lacking so far.
Due to the rising number of campylobacteriosis case
notiﬁcations in recent years, we conducted several
studies which aimed at generating a better understand-
ing of the epidemiology of campylobacteriosis in
Switzerland. We investigated epidemiological determi-
nants [29], described time trends in notiﬁcation data
[1], the campylobacteriosis-associated illness experi-
ence from the patients’ perspective [29, 30], the case
management strategies of GPs (Supplementary mater-
ial) and laboratory positivity rates of Campylobacter
spp. (Supplementary material). In concert, these
studies indicate that campylobacteriosis is causing a
considerable burden of disease which considerably
impacts the health system in Switzerland and is likely
associated with high costs.
The aim of this study was to estimate the total an-
nual costs for the medical treatment of campylobacter-
iosis in Switzerland. However, given that available data
do not systematically distinguish campylobacteriosis
from AG we focused this analysis on available data
of both conditions. To the best of our knowledge,
this is the ﬁrst study estimating healthcare costs due
to AG and campylobacteriosis in Switzerland.
METHODS
We developed patient management models and esti-
mated their frequency and associated costs from the
perspective of the healthcare system.
Typology of patients: patient management models
Cost estimation was based on four different patient
management models for AG which were derived from
a broad expert consultation across a purposive enquiry
among practitioners in private general and specialized
practices (four), clinics and university hospitals (four),
authors opinions and data available to them: (i) patients
consulting a physician without stool testing (patient
management model A), (ii) patients consulting a
physician with negative Campylobacter stool test results
(patient management model B), (iii) patients consulting
a physician and having a positive Campylobacter stool
test result (patient management model C), and (iv) hos-
pitalized campylobacteriosis cases (patient management
model D).
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Table 1. Overview of selected studies estimating the cost of illness of gastrointestinal or foodborne illnesses
First
author, year
[ref.] Nation Year
Pathogens/disease
considered
(community cases,
unless speciﬁed
otherwise)
Cases per
year
Costs includeda
Exchange
rate used
(€1 = . . .)c
Direct
healthcare
cost, per
case (in €)
Direct
healthcare
cost, yearly
(in million €)
Total costs
per case
(in €)
Total yearly
costs (in
million €)
Direct
healthcare
cost
Patient
costs
(e.g.
travel
costs)
Productivity
losses Othersb
Hoffmann,
2015 [10]
United States 2013 15 foodborne
pathogens
including
long-term
disabilities; only
domestically
acquired and
foodborne cases
8 914 713 X X X USD 1·34 155d 1384 1305d 11 636
Mangen,
2015 [11]
Netherlands 2011 14 foodborne
pathogens;
including
sequelae
4810000 X X X EUR 1 31d 147 97d 468
Scharff,
2012 [12]
United States 2010 All domestically
acquired,
foodborne
illnesses
47 780 778 X X X USD 1·33 75 3568d 806–1227 38 506–
58 589
Friesema,
2012 [13]
Netherlands 2009 Gastroenteritis 4 600 000 X X X EUR 1 14d–32d 63–147 133–151 611–695
Gauci, 2007
[14]
Malta 2004/05 Infectious
intestinal disease
164 471 X X X Lm 0·44e 72d 12 108 17
Abelson,
2006 [15]
Australia 2004 Gastroenteritis
due to foodborne
illnesses
5 400 000f X X X AUD 1·69 22d 118 111d 598
Majowicz,
2006 [16]
City of
Hamilton,
Canada
2001 Acute
gastroenteritis
619 334g X X CAD 1·39 17d 11d 66 40
Van den
Brandhof,
2004 [17]
Netherlands 1999 Gastroenteritis 4 476 399 X X X EUR 1 14 61 77 345
Roberts,
2003 [18]
England 1994 Infectious
intestinal disease
9 400 000h X X X GBP 0·66
(year
1999)
16d–44d 153–412 109d–120 1028–1128
Hellard,
2003 [9]
Australia 1999 Highly credible
gastroenteritis
15 173 430 X X AUD 1·65 3d 46 14d 208
H
ealthcare
costs
of
acute
gastroenteritis
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Table 1 (cont.)
First
author, year
[ref.] Nation Year
Pathogens/disease
considered
(community cases,
unless speciﬁed
otherwise)
Cases per
year
Costs includeda
Exchange
rate used
(€1 = . . .)c
Direct
healthcare
cost, per
case (in €)
Direct
healthcare
cost, yearly
(in million €)
Total costs
per case
(in €)
Total yearly
costs (in
million €)
Direct
healthcare
cost
Patient
costs
(e.g.
travel
costs)
Productivity
losses Othersb
Lindqvist,
2001 [19]
Municipality
of Uppsala,
Sweden
1999 Foodborne
illnesses
500 000i
(Sweden)
X X SEK 8·81 117 58d 246 123
Scott, 2000
[20]
New Zealand 1999 Foodborne
infectious disease
119 320 X X X X NZD 2·01 9d 1·0 229 27
Karve, 2014
[21]
United States 2010/11 Acute
gastroenteritis;
only cases
consulting a
physician,
visiting
emergency
department and
inpatient care
setting
6 668 944j X USD 1·36 472d 3151 472 3151
a Categories represent only a very broad classiﬁcation of costs included in the studies. Certain items may be included in different categories, depending on the study. For
example, transportation cost was sometimes considered as ‘direct healthcare cost’ (when covered by the health system) and sometimes included in ‘patient costs’.
b For example, food recalls, or intangible costs for reduced quality of life (intangible costs are monetary representations of pain, suffering and fear which can be obtained
through willingness-to-pay studies [22]), or value of statistical life for premature deaths.
c Average exchange rates of the calendar year when the study was conducted (as indicated in the column ‘year’) were used and extracted from [23].
d Calculated based on yearly case numbers and either costs per case (for calculating yearly costs) or yearly costs (for calculating costs per case) as reported in the original
publication.
e Exchange rate as indicated in the original publication (1 Maltese lira = €2·29).
f According to Hall et al. 2005 [24].
g Calculated based on a population size of 490 290 and 126 320 cases/100 000 population as reported in the original publication.
h Calculated based on total yearly costs (£742·8 million) divided by total costs per case (£79) as reported in the original publication, rounded to the next 100 000.
i According to Norling, 1994 [25].
j Sum of estimated annual episodes of acute gastroenteritis in physician’s ofﬁce (5 337 473), emergency department (1 032 064) and inpatients (447 580) as reported in the ori-
ginal publication.
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Table 2. Overview of selected studies estimating the cost of illness of campylobacteriosis
First
author,
year [ref.] Nation Year
Pathogens/disease
considered
(community cases, unless
speciﬁed otherwise)
Sequelae
considered
Cases
per year
Costs includeda
Exchange rate
used (€1 = . . .)c
Direct
healthcare
cost, per
case (in €)
Direct
healthcare
cost, yearly
(in million
€)
Total
costs
per
case
(in €)
Total yearly
costs (in
million €)
Direct
healthcare
cost
Patient
costs
(e.g.
travel
costs)
Productivity
losses Othersb
Hoffmann,
2015 [10]
United
States
2013 Campylobacter spp.; only
domestically acquired
and foodborne cases
GBS 845 024f X X X USD 1·34 253d 213 1710 1445
Mangen,
2015 [11]
Netherlands 2011 Campylobacter spp. GBS, ReA,
IBS, IBD
108 000 X X X EUR 1 280d 30 757 82
Scharff,
2012 [12]
United
States
2010 Campylobacter spp.; only
domestically acquired
and foodborne cases
GBS, ReA 845 024e X X X USD 1·33 163 138d 1392–
6141
1177–5189
Gellynck,
2008 [26]
Belgium 2004 Campylobacter-associated
gastroenteritis and
sequelae
GBS, ReA,
IBD
55 000 X X X EUR 1 n.a. n.a. 497d 27
Mangen,
2005 [8]
Netherlands 2000 Campylobacter spp. and
sequelae
GBS, ReA,
IBD
79 000 X X X EUR 1 82d 6·5 261d 21
Van den
Brandhof,
2004 [17]
Netherlands 1999 Campylobacter spp. Not
considered
79 000f X X X EUR 1 n.a. n.a. 117d 9
Scott, 2000
[20]
New
Zealand
1999 Proportion of foodborne
Campylobacter spp.
GBS, ReA,
HUS
75 345 X X X X NZD 2·01 8d 0·6 265 20
Roberts,
2003 [18]
England 1994 Campylobacter spp. Not
considered
n.a. X X X GBP 0·66
(year 1999)
n.a. 15 n.a. 106
GBS, Guillain–Barré Syndrome; HUS, haemolytic uraemic syndrome; IBD, inﬂammatory bowel disease; IBS, irritable bowel syndrome; n.a., not available; ReA, reactive
arthritis.
a Categories represent only a very broad classiﬁcation of costs included in the studies. Certain items may be included in different categories, depending on the study. For
example, transportation cost was sometimes considered as ‘direct healthcare cost’ (when covered by the health system) and sometimes included in ‘patient costs’.
b For example, food recalls, or intangible costs for reduced quality of life (intangible costs are monetary representations of pain, suffering and fear which can be obtained
through willingness-to-pay studies [22]), or value of statistical life for premature deaths.
c Average exchange rates of the calendar year when the study was conducted (as indicated in the column ‘year’) were used and extracted from [23].
d Calculated based on yearly case numbers and either costs per case (for calculating yearly costs) or yearly costs (for calculating costs per case) as reported in the original
publication.
e According to Scallan et al. 2011 [27].
f Assumed, according to Mangen et al. 2005 [8].
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Population ﬁgures as basis for modelling: sources and
approach
The number of notiﬁed campylobacteriosis cases occur-
ring each year in Switzerland was retrieved from the
NNSID [1]. A study assessing the trend in
Campylobacter positivity rates was conducted (there-
after referred to as the ‘Positivity study’). This study
used data of eight Swiss diagnostic laboratories on
Campylobacter tests performed between 2003 and
2012. Positivity rates, deﬁned as the proportion
of Campylobacter-positive to total number of
Campylobacter tests, were calculated. The number of
Campylobacter tests performed in Switzerland was esti-
mated based on the preliminary positivity rate of 2012.
In 2013, a qualitative study among 69 GPs was
conducted in Switzerland (thereafter referred to as
the ‘Swiss GP study’). Using a semi-structured ques-
tionnaire, physicians were interviewed about their
case management strategies for and general perception
of AG and campylobacteriosis. From this study, GPs’
estimates on the proportion of AG patients with a
stool test prescribed were available.
In 2014, the Swiss Sentinel Surveillance Network
decided to study AG for 12 months; 170 participating
GPs reported all cases consulting due to AG. This
study (thereafter referred to as the ‘Sentinella study’)
also provides estimates on the proportion of patients
with a stool test.
The results used for cost estimates from the
‘Positivity’, the ‘Swiss GP’ and the ‘Sentinella study’
are preliminary. Short summaries of these studies includ-
ing the preliminary results used for estimating healthcare
costs can be found in the Supplementary material. Final
results of all these studies will be published separately.
We used the number of hospitalizations due to the
ICD-10 code ‘A04·5 Campylobacter enteritis’ as
reported in ofﬁcial hospital statistics published by
the Federal Statistical Ofﬁce [31]. We compared this
number with estimates based on the hospitalization
rate found in our case-control study on determinants
of campylobacteriosis [29] and the number of campy-
lobacteriosis case notiﬁcations from the NNSID [1].
Population-level estimates
The number of campylobacteriosis cases registered at
the FOPH was assumed to correspond to the number
of patients in management models C and D in the
whole of Switzerland. The number of hospitalizations
in Switzerland (patient management model D)
was extracted from ofﬁcial hospital statistics
(hospitalizations due to Campylobacter enteritis,
ICD-10 code A04·5) [31].
Patients in management model D
= cases hospitalized due to ICD-10 code A04.5,
Patients in management model C = cases in NNSID
− patients in management model D.
The proportion of positive to total number of cam-
pylobacteriosis tests was used to estimate the number
of patients in management model B based on notiﬁed
cases (hence, cases with a positive test result).
Patients in management model B
= cases in NNSID
positivity rate = positive tests in x labsall tests in x labs
( )
− cases in NNSID.
The proportion of patients with stool testing (as
opposed to consultation without stool testing) was used
to estimate case numbers for patient management
model A.
Patients in management model A
= [( patients in management model B +cases in NNSID = all tested( ) )proportion of patients with stool test ]
− all tested.
The data sources used for the extrapolation from in-
dividual to population-based costs are summarized in
Figure 1a.
Healthcare expenditures
Healthcare costs for each of the patient management
models were estimated by combining associated med-
ical standard procedures with publicly available re-
spective rates for accounting. We extrapolated these
individual case management costs to estimate health-
care costs associated with AG and campylobacteriosis
in Switzerland in 2012.
Sources of cost data
We used different sources in order to calculate health-
care expenditure due to Campylobacter infections:
from the Swiss GP study, based on expert opinions
and using preliminary results of the Sentinella study,
treatment schemes and standard approaches for case
management (including number and duration of
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consultations, laboratory tests performed and medica-
tions prescribed) were identiﬁed. Consultation costs of
GPs were calculated using the number of points from
the publicly available Swiss medical tariff system,
TARMED (as of June 2012) [32] and a point value of
€0·7138 which is used in the canton of Bern [33].
Similarly, points for laboratory diagnostics were
extracted from the ofﬁcial tariff list (‘Analysenliste’; as
of January 2012) using a point value of €0·83 applied
throughout Switzerland [34]. Costs for medications
were extracted from the list of pharmaceutical special-
ities (‘Spezialitätenliste’, version of 1 January 2012)
[35]. Calculation of hospitalization costs was based on
the ﬂat rates of the Swiss diagnosis-related group-based
(DRG-based) hospital reimbursement system and a
base rate which is applied by several regional hospitals
in the canton of Bern, both for 2012 [36, 37]. Costs in
Swiss francs were converted to Euros using an exchange
rate for the Euro of €0·83 per Swiss franc (average
exchange rate January 2012–December 2012) [23].
The cost estimation process for the patient management
models is presented in Figure 1b.
We obtained primary cost data from invoices for
consultations of Campylobacter-positive patients, cov-
ering all patient consultations between 2011 and 2013
at the Swiss TPH travel clinic. This part of the
study was approved by the local ethical committee
(Ethikkommission Nordwest- und Zentralschweiz
ref. no. EKNZ: 2014–159).
Data analysis
Costs per patient treated
Differentiating by patient management model (models
A–D), we evaluated the costs for consultations,
medication, laboratory tests and hospitalization until
conclusion of medical treatment. For all patient man-
agement models we deﬁned two scenarios to account
for some of the heterogeneity of the patients and the
case management strategies within a given model: a
minimal and an extended or prolonged scenario. The
proportions of patients treated with the minimal and
the extended scenario were estimated based on results
of the case-control (e.g. proportion of patients treated
with antibiotics) [29] and the Sentinella study (e.g.
number of consultations; Supplementary material).
Afterwards, experts were asked whether they considered
the estimated proportions reasonable. The two scen-
arios do not imply any chronology of the steps involved.
Estimates for patient management model C were
validated using real patient records of the Swiss TPH
travel clinic. Patient invoices were entered in an
electronic database and analysed using Stata v. 13
(StataCorp., USA). Costs for laboratory tests or medi-
cation not primarily associated with AG were excluded,
i.e. tests for Echinococcus, Filaria, ﬂavivirus and
Plasmodium, vaccines for rabies and tetanus, and elec-
trocardiograms. Laboratory tests performed in external
laboratories were invoiced by these laboratories and
Fig. 1. Overview of data sources used for (a) extrapolation of treatment costs and (b) for cost estimation for acute
gastroenteritis and campylobacteriosis patients. a Qualitative study about case management of campylobacteriosis patients
among 69 general practitioners in Switzerland (Supplementary material). b Study on acute gastroenteritis conducted within the
Swiss Sentinel Surveillance Network ‘Sentinella’ (www.sentinella.ch) in 2014 (Supplementary material). c Study on laboratory
positivity rates of Campylobacter, Salmonella and Shigella diagnostic tests in Switzerland (Supplementary material).
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could, hence, not be considered in our analysis.
However, we added costs for one positive stool test
for Campylobacter spp. as patients were selected based
on having laboratory-conﬁrmed campylobacteriosis.
RESULTS
Frequency of different patient management models in
Switzerland
In the NNSID, 8480 cases of campylobacteriosis were
registered in 2012 [1]. Preliminary results from the
Positivity study showed that 10·9% of all campylobac-
teriosis tests were positive (Supplementary material).
Consequently, we estimated that 77 798 tests for
Campylobacter spp. were made in 2012, of which
69 318 had a negative test result (patient management
model B). Estimates of the Swiss GP study indicated
that one in four AG patients has a stool test per-
formed (Supplementary material), suggesting that
233 394 patients consult a physician each year without
further stool testing (patient management model A).
However, preliminary results from the Sentinella
study suggest that only 11% (420/3794) of patients
had stool testing performed (Supplementary material).
In this case a total of 629 457 patients would be in
patient management model A.
The number of hospitalizations due to
‘Campylobacter enteritis’ (ICD-10 code A04·5) as
reported in the ofﬁcial Swiss hospital statistics increased
steadily since 2004. In 2012, 1348 hospitalizations were
reported which is the maximum so far (Fig. 2). For
comparison, 14·5% (23/159) of interviewed patients in
the recent case-control study, with laboratory-
conﬁrmed campylobacteriosis, reported hospitalization
due to their illness [29]. Considering the case notiﬁca-
tion numbers of 2012 (8480 cases), this proportion
would result in 1230 hospitalizations (patient manage-
ment model D). Patient management model C includes
all notiﬁed cases except those being hospitalized (1348),
resulting in 7132 patients annually in Switzerland.
Individual case management costs for AG and
campylobacteriosis patients
The costs per case are highly variable ranging from
€30 (patient management model A) to €4828 (patient
management model D). The cost items attributed to
the different patient management models and scen-
arios and associated costs are presented in Table 3.
(For a list of unit costs see Supplementary Table S2.)
The healthcare costs of 41 patients with laboratory-
conﬁrmed Campylobacter spp. infection were ana-
lysed. Costs for those 19 male and 22 female patients
aged between 1 and 72 years were in the range of
€179–1033 (median €464). The number of consulta-
tions varied between 1 and 8 per patient (median 2),
Fig. 2. Number of hospitalizations due to ICD-10 code A04·5 ‘Campylobacter enteritis’ in Switzerland from 2004 to 2012
( , left axis, [31]), number of hospitalizations extrapolated from results of a case-control study in Switzerland [29]
assuming hospitalization of 14·5% of cases registered in the National Notiﬁcation System for Infectious Diseases (NNSID)
( , left axis) and number of case notiﬁcations from the NNSID [1] ( ; right axis).
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Table 3. Healthcare costs associated with the management of acute gastroenteritis and campylobacteriosis for four patient management models with two scenarios
each (values reﬂect costs in €)
Patient management model A
Consultation without stool test
Patient management model B
Consultation with negative stool
culturea
Patient management model C
Consultation with positive stool
culturea
Patient management model D
Hospitalization
Minimal scenario 10 min consultationb 19·02 15 min consultationb 31·69 15 min consultationb 31·69 15 min consultationb 31·69
1 medicationc 10·79 Stool culturea (negative) 64·74 Stool culturea (positive) 128·65 Hospital stay (DRG
G67Be)
4727·36
Taking blood sample 5·85 Taking blood sample 5·85
Haemogramd and CRP 18·26 Haemogramd and CRP 18·26
1 medicationc 10·79 1 medicationc 10·79
5 min reviewing patient
ﬁle
12·68 5 min reviewing patient
ﬁle
12·68
5 min telephone cons. 12·68 5 min telephone
consultation
12·68
Total, minimal scenario 29·81 156·68 220·59 4759·06
Extended scenario + Taking blood
sample
5·85 + Antibiotic 24·90 + Antibiotic 24·90 + 5 min reviewing
patient ﬁle
12·68
(costs additional to minimal scenario) + Haemogramd and
CRP
18·26 + Pharmacy feesf 6·27 + Pharmacy feesf 6·27 + Taking blood
sample
5·85
+10 min second
consultationb
19·02 +10 min second
consultationb
19·02 +10 min second
consultationb
19·02 + Haemogramd and
CRP
18·26
+ 15 min second
consultationb
31·69
Total, extended scenario 72·93 206·87 270·78 4827·53
Proportion of patients requiring extended
scenario:
20% 40% 65% 50%
Data sources
Expert opinion x x x x
TARMEDg [32] x x x x
List of pharmaceutical specialities [35] x x x x
Ofﬁcial laboratory tariff list [34] x x x x
Flat rates of Swiss DRG, version 1.0 [36] x
Swiss GP studyh x x x
Sentinella studyi x x x
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Table 3 (cont.)
Patient management model A
Consultation without stool test
Patient management model B
Consultation with negative stool
culturea
Patient management model C
Consultation with positive stool
culturea
Patient management model D
Hospitalization
Swiss TPH travel clinic x
CRP, C-reactive protein; NNSID, National Notiﬁcation System for Infectious Diseases.
a Stool culture includes Campylobacter, Salmonella and Shigella.
b Or telephone consultation of same duration.
c Of the following medications: antidiarrhoeal, antiemetics, probiotics; average price of those medications: €10·79 (13 CHF).
d Including erythrocytes, leucocytes, haemoglobin, haematocrit, thrombocytes, and 55 subpopulations of leucocytes.
e For a patient with Campylobacter enteritis (ICD-10 code A04·5), aged 51 year, with a length of stay between 2 and 11 nights, the DRG group ‘G67B’ is assigned. Cost
weight: 0·573, base rate (applied by several regional hospitals in Bern): €8250·20 (9940 CHF) [37]. Quote from Swiss DRG version 1.0 [36] deﬁning code ‘G67B’:
[translated from German] ‘Oesophagitis, gastroenteritis and other diseases of the digestive organs with a complex diagnosis or age <1 year or gastrointestinal bleeding,
with very severe or severe complications or comorbidities or age >74 years or peptic ulcer disease with severe complications or comorbidities or age >74 year, hospital oc-
cupancy > 1 day, without complicating diagnosis, without dialysis’.
f Fees include check of the prescription which can be invoiced once per item prescribed (‘Medikamenten-Check’; €3·57, CHF 4·30) and check of the purchase which can be
invoiced once per patient, per day and per provider (‘Bezugs-Check’; €2·70, CHF 3·25) [49].
g Costs vary among cantons; median costs are used (tariff point value €0·7138 or 0·86 CHF, e.g. canton Bern) [33].
h Qualitative study about case management of campylobacteriosis patients among 69 general practitioners in Switzerland (Supplementary material).
i Study on acute gastroenteritis conducted within the Swiss Sentinel Surveillance Network ‘Sentinella’ (www.sentinella.ch) in 2014 (Supplementary material).
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the number of blood samples taken between 0 and 4
(median 1) and the time between the ﬁrst and the
last consultation between 0 (only one consultation)
and 65 days (median 3). Consultation costs and
costs for laboratory testing of real patient data were
higher than estimated costs for patient management
model C (Supplementary Table S3).
Healthcare costs due to AG and campylobacteriosis
Total healthcare costs for the management of the four
different patient management models combined in
Switzerland in 2012 were estimated at €29·5–44·7 mil-
lion (Table 4). Costs for the different patient manage-
ment model groups (A–D) were €9·0–24·2, €12·3,
€1·8 and €6·5 million, respectively (Supplementary
Fig. S1).
Costs separated by type/provider were: €11·1–20·6
million for GPs’ services (including medical assis-
tants), €7·7–9·1 million for laboratory diagnostics,
€4·4–8·6 million for medications and €6·4 million for
hospitalizations (Supplementary Fig. S2).
DISCUSSION
This study provides for the ﬁrst time an assessment of
total Swiss healthcare costs due to AG and campylobac-
teriosis by estimating the individual costs of four types
of patient management models and their frequency:
patients suffering from AG and seeking medical care
without being tested (model A); patients seeking medical
care and having a Campylobacter-negative stool test
(model B); patients seeking medical care and having a
Campylobacter-positive stool test (model C); and
patients with a severe course of campylobacteriosis re-
quiring hospitalization (model D).
Cases of campylobacteriosis increased in the last
decade 1·5-fold, implying a contemporarily relevant
public health problem. We estimated that in
Switzerland, each year 311 192–707 255 patients con-
sult a physician due to AG or campylobacteriosis,
leading to annual healthcare costs ranging from €29
to €45 million.
The calculations were based on several assumptions
as this study provides the ﬁrst estimates of health-
care costs due to AG and campylobacteriosis in
Switzerland. The country has no central database
which is based on diagnostic codes and where health-
care costs from outpatient care are systematically
recorded. Therefore, we tried to cross-validate our
estimates whenever possible by combining different
data sources. The real patient data which we used
for comparison with cost estimates for patient man-
agement model C originated from our own institu-
tion’s (Swiss TPH) travel clinic. These real patient
data suggested higher costs for laboratory-conﬁrmed,
ambulatory patients than we used for our calculations.
Possibly consultation time in returning travellers was
longer because of the travel anamnesis and laboratory
tests were more extensive. Nevertheless, returning tra-
vellers are likely to be overrepresented also in the
patients with AG seen by GPs. When using the
Table 4. Estimated healthcare costs for the treatment of acute gastroenteritis and campylobacteriosis in Switzerland.
Costs for individual cases are based on resource use estimates presented in Table 3
Patient
management
model ASentinella
Patient
management
model ASwiss GP
Patient
management
model B
Patient
management
model C
Patient
management
model D
Estimated number of cases (n) 629 457 233 394 69 318 7132 1348
In minimal scenario 503 566 186 715 41 591 2496 674
In extended scenario 125 891 46 679 27 727 4636 674
Consultation €11 969 523 €4 438 134 €4 359 611 €448 552 €42 722
Laboratory diagnostics €0 €0 €5 753 394 €1 047 762 €0
Medication €6 791 841 €2 518 321 €747 941 €76 954 €0
Hospitalization €0 €0 €0 €0 €6 372 487
+Consultation €3 129 858 €1 160 517 €527 246 €88 156 €33 845
+Laboratory diagnostics €2 298 770 €852 359 €0 €0 €12 307
+Medication €0 €0 €864 154 €144 488 €0
Healthcare costs by patient
management model
€24 189 992a €8 969 331a €12 252 346a €1 805 913a €6 461 362a
Total healthcare costs €29 488 953–44 709 613a
a Totals do not always add up because of rounding.
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median total costs of the real patient data of the travel
clinic for patients in management model C, the costs
for this group would be €3·3 million (instead of €1·8
million; Supplementary Figs S1 and S2). Hence, we
believe the cost estimates used for patient manage-
ment model C are conservative.
Some physicians reported performing a second stool
test after a positive result for certain patient groups (e.g.
working in the food sector) before allowing the patients
to return to work. A few experts claimed that the con-
sultation times we applied in our models were rather
short. They suggested consultation times of 5–10 min
longer for selected (but not for all) consultations. The
case-control study [29] found that about 10% of campy-
lobacteriosis patients in outpatient treatment received
intravenous therapy, which was not considered in our
models. Furthermore, patients requiring hospitalization
may be transferred to the hospital by ambulance caus-
ing additional costs. Taking all these points into ac-
count, we believe that our estimates reﬂect rather
conservative approximations.
Healthcare costs of laboratory-conﬁrmed
campylobacteriosis patients
Campylobacteriosis cases as registered in the NNSID
were estimated to cost around €8·3 million/year (patient
management models C and D). The majority of these
costs are attributable to hospitalizations. Comparison
of our estimates with actual patient data suggests
that our estimates (at least for patient management
model C) underestimated actual costs occurring in
the health system. The number of hospitalizations
due to ‘Campylobacter enteritis’ (ICD-10 code
A04·5) matches well with the calculated number of
hospitalized patients using the ofﬁcial notiﬁcation
data together with the hospitalization rate found in
the case-control study (1348 vs. 1230 cases). The hos-
pitalization costs, which are based on DRG ﬂat rates,
include all costs occurring during the hospital stay.
This ﬂat rate is independent of the length of stay as
long as it is within 2–11 nights (for DRG code
G67B, according to DRG v. 1.0 [36]).
Healthcare costs of AG patients
The costs for AG patients without laboratory-
conﬁrmed campylobacteriosis varied signiﬁcantly de-
pending on the proportion of stool testing we used
to calculate patient numbers for patient management
model A. The proportion of stool testing is highly
variable also in other countries: it was found to be
12% in The Netherlands [38], 19–44% in the United
States [39, 40] and 27% in England [41]. Even though
our estimate of 11% from the Sentinella study is lower
compared to the proportions reported in other coun-
tries we believe that this number is more accurate
than the semi-quantitative estimates obtained from
the Swiss GP study. Moreover, the ﬁgure from the
Sentinella study represents the proportion of patients
for which the physician initiated stool testing. It is
likely that not all patients actually provided a stool
specimen. Hence, using the proportion of actually
completed stool tests would increase case numbers in
model A and our cost estimates. Additionally, our cal-
culation for patient management model A is based on
the estimated number of tests for Campylobacter spp.
This may in fact underestimate the total number of
stool tests as in some instances physicians might
only test their patients for viruses, for example. In
this case, the number of patients in management mod-
els A and B would be even larger.
Apart from Campylobacter both Salmonella and
Shigella infections are notiﬁable in Switzerland.
Usually, basic stool bacteriology involves testing for
these three pathogens [42]. Under this assumption
and ignoring the chance of mixed infections, all
Salmonella- or Shigella-positive patients were assigned
to management model B (patients with Campy-
lobacter-negative stool test). This leads again to a
rather conservative estimate of costs since stool cultures
with a positive result are more expensive than negative
stool cultures (€64·74 vs. €128·65) [34]. Additionally,
salmonellosis and shigellosis patients may also need
hospitalization and those patients are, therefore, more
likely to create costs similar to those estimated for
campylobacteriosis patient management models C
and D. In 2012, 1243 cases of salmonellosis and 159
cases of shigellosis were reported [43, 44]. Moreover,
AG patients with viral infections and patients without
an identiﬁed causative agent might be hospitalized.
The hospitalization costs for these patients were not
considered in our study.
Patients consulting a physician not at all or only by
phone and patients seeking help in a pharmacy have
not been considered in this study. Up to 60% of
gastroenteritis patients calling the medical practice are
managed by phone, according to the Swiss GP study
(Supplementary material). Individual (healthcare)
costs for these patients may be low. However, the
high quantity of these patients might still lead to con-
siderable costs.
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Comparison of cost estimates for Switzerland with
estimates of other countries
Various studies have been conducted in several coun-
tries to estimate costs for gastrointestinal infections or
campylobacteriosis (Tables 1 and 2). However, com-
parison of costs is very difﬁcult due to varying case
deﬁnitions used, heterogeneity in costs included,
differences in health systems and health-system use
and time. We estimated that a case of laboratory-
conﬁrmed campylobacteriosis costs on average €975
(average per case for models C and D). The extent
of underreported campylobacteriosis infections –
deﬁned as infections in individuals who seek healthcare
but whose infection is not captured by the surveillance
system [45] – is unknown for Switzerland. The multi-
plication factor due to underreporting of campylobac-
teriosis was estimated at 1·3 in the UK [46] and at
2·0–5·6 in The Netherlands [6, 47]. Applying the
same factors to Swiss data would result in 2544–
39 008 additional campylobacteriosis cases. Assuming
that underreporting was due to under-diagnosis (as
opposed to under-notiﬁcation), these cases are auto-
matically included in our patient management model
A (where model A represents all consulting AG
patient without stool diagnostics.) Hence, costs in
model A attributable to under-diagnosed campylobac-
teriosis cases would range between €0·98 and €1·50
million. Total costs attributable to campylobacteriosis
would then range between €8·4 and €9·8 million in
Switzerland (representing 19–33% of total AG costs)
or €206–759/case. Healthcare costs per case are higher
than Dutch (€82–280/case, Table 2) or US estimates
(€163–253/case). However, the latter two were based
on the yearly estimated number of campylobacteriosis
cases in the population while we considered only cam-
pylobacteriosis cases presenting to the GP or being
hospitalized.
On average, a case of AG (including campylobac-
teriosis) in Switzerland was estimated at €63–95.
Again, our cost estimates are based on cases present-
ing to the GP while estimates from other countries
usually are presented for cases in the community.
Hence, values are not comparable even though our
cost estimates are within the range of cost estimates
from other countries (€3–155 [9–20], Table 1).
Unknown socioeconomic burden
We only assessed direct healthcare costs for AG and
campylobacteriosis. The average hospital stay of
three nights and the median disease duration of 7
days of campylobacteriosis patients which were
found in the case-control study [29] suggest that the
socioeconomic burden due to productivity loss and
home care is a multiple of the healthcare costs.
Additionally, we neither considered costs arising
from complications of the disease (e.g. Guillain–
Barré syndrome, reactive arthritis or irritable bowel
syndrome) nor did we include out-of-pocket expenses
for medications of patients not consulting a physician
or costs arising of patients consulting the physician ex-
clusively by phone. This further underscores the con-
servative nature of our overall healthcare cost
estimated at €29–45 million.
The disease burden and economic consequences are
further increased by years of life lost due to premature
mortality. The ICD-10 codes A02 ‘other Salmonella
infections’ and A04·5 ‘Campylobacter enteritis’ were
recorded only for four patients in 2011 as the main
cause of death (Swiss Federal Statistical Ofﬁce, per-
sonal communication). When considering also sec-
ondary causes of deaths, 104 deaths were registered
in 2011. For inﬂuenza it was shown that mortality is
underreported in ofﬁcial statistics [48]. We assume
that such underreporting is also the case for deaths
due to campylobacteriosis (and salmonellosis).
AG and campylobacteriosis cause a marked public
health problem generating considerable costs. To our
knowledge, this is the ﬁrst study investigating health-
care costs due to AG and campylobacteriosis in
Switzerland. Further research is needed for more ac-
curate cost estimation. In order to reduce the ﬁnancial
burden and suffering of patients, there is a need for
implementing health policy measures, sectorial and
inter-sectorial public health interventions and increas-
ing awareness in the population at all levels.
SUPPLEMENTARY MATERIAL
For supplementary material accompanying this paper
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